Drug Patents owned by Astrazeneca Ab
1. Drug name - BREZTRI AEROSPHERE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9463161 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems |
May, 2030
(7 years from now) | |
| US8703806 | ASTRAZENECA AB | Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents |
May, 2030
(7 years from now) | |
| US8808713 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(7 years from now) | |
| US8324266 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(7 years from now) | |
| US9415009 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
May, 2030
(7 years from now) | |
| US10716753 | ASTRAZENECA AB | Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems |
May, 2030
(7 years from now) | |
| US8815258 | ASTRAZENECA AB | Compositions, methods and systems for respiratory delivery of two or more active agents |
Mar, 2031
(8 years from now) | |
Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient
Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)
Dosage: AEROSOL, METERED;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.16MG/INH;0.0048MG/INH;0.009MG/INH | AEROSOL, METERED;INHALATION | Prescription |
2. Drug name - BYDUREON
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(3 years from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(4 days from now) | |
|
US6824822
(Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(6 months from now) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 6 months from now) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 6 months from now) | |
|
US9238076
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 years from now) | |
|
US7563871
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 years from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(2 years from now) | |
|
US8461105
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(3 years from now) | |
|
US7612176
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(3 years from now) | |
|
US8431685
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(3 years from now) | |
|
US7456254
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(3 years from now) | |
|
US6515117
(Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(3 years from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(3 years from now) | |
|
US8906851
(Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(4 years from now) | |
|
US8329648
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
|
US9884092
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| US8758292 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Nov, 2027
(5 years from now) | |
|
US8501698
(Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(5 years from now) | |
| US8216180 | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jan, 2028
(5 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US8439864 | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Mar, 2028
(5 years from now) | |
| US9320853 | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Mar, 2028
(5 years from now) | |
|
US8758292
(Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
May, 2028
(5 years from now) | |
|
US8216180
(Pediatric) | ASTRAZENECA AB | Administering apparatus with functional drive element |
Jul, 2028
(5 years from now) | |
|
US8361972
(Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(5 years from now) | |
|
US9320853
(Pediatric) | ASTRAZENECA AB | Method for administering a fluid active substance from a multi-chamber ampoule |
Sep, 2028
(5 years from now) | |
|
US8439864
(Pediatric) | ASTRAZENECA AB | Device for administering fluid from a multi-chamber ampoule in incremental steps |
Sep, 2028
(5 years from now) | |
| US8827963 | ASTRAZENECA AB | Administering device with holding mechanism |
Feb, 2029
(6 years from now) | |
| US8690837 | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
May, 2029
(6 years from now) | |
|
US8827963
(Pediatric) | ASTRAZENECA AB | Administering device with holding mechanism |
Aug, 2029
(6 years from now) | |
|
US8690837
(Pediatric) | ASTRAZENECA AB | Mixing device for a two-chamber ampoule |
Nov, 2029
(7 years from now) | |
| US8998876 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(7 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(7 years from now) | |
|
US8998876
(Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(7 years from now) | |
|
US8721615
(Pediatric) | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jul, 2030
(7 years from now) | |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; Reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin
Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 2MG/VIAL | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | Discontinued |
| 2MG | FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | Discontinued |
3. Drug name - BYDUREON BCISE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(3 years from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6824822 | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Oct, 2022
(4 days from now) | |
|
US6824822
(Pediatric) | ASTRAZENECA AB | Residual solvent extraction method and microparticles produced thereby |
Apr, 2023
(6 months from now) | |
| US7563871 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 6 months from now) | |
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 6 months from now) | |
|
US9238076
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 years from now) | |
|
US7563871
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2024
(2 years from now) | |
| US7612176 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(2 years from now) | |
|
US8461105
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(3 years from now) | |
|
US7612176
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(3 years from now) | |
|
US8431685
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Oct, 2025
(3 years from now) | |
|
US7456254
(Pediatric) | ASTRAZENECA AB | Polymer-based sustained release device |
Dec, 2025
(3 years from now) | |
|
US6515117
(Pediatric) | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Apr, 2026
(3 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(3 years from now) | |
| US9884092 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
|
US8906851
(Pediatric) | ASTRAZENECA AB | Method for treating diabetes |
Feb, 2027
(4 years from now) | |
|
US9884092
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
|
US8329648
(Pediatric) | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Feb, 2027
(4 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
|
US8501698
(Pediatric) | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2027
(5 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
|
US8361972
(Pediatric) | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Sep, 2028
(5 years from now) | |
| US8895033 | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Oct, 2030
(8 years from now) | |
|
US8895033
(Pediatric) | ASTRAZENECA AB | Sustained release formulations using non-aqueous carriers |
Apr, 2031
(8 years from now) | |
Drugs and Companies using EXENATIDE SYNTHETIC ingredient
Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; stimulating insulin release in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; delaying gastric emptying in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication
Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
| Strength | Dosage | Availability |
|---|---|---|
| 2MG/0.85ML (2MG/0.85ML) | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | Prescription |
4. Drug name - FARXIGA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(3 years from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(7 years from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN103319445B | ASTRAZENECA AB | Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof |
Jun, 2027
(4 years from now) | |
| CN101479287A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773B | ASTRAZENECA AB | Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid |
Jun, 2027
(4 years from now) | |
| CN101479287B | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445A | ASTRAZENECA AB | Sglt2 Inhibitor Crystal Structure And Its Preparation Method |
Jun, 2027
(4 years from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP3045466A1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374B1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374A1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3045466B1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807A1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP3363807B1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP2069374B2 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9238076 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2024
(1 year, 6 months from now) | |
| US8431685 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US8461105 | ASTRAZENECA AB | Polymer-based sustained release device |
Apr, 2025
(2 years from now) | |
| US7456254 | ASTRAZENECA AB | Polymer-based sustained release device |
Jun, 2025
(2 years from now) | |
| US8906851 | ASTRAZENECA AB | Method for treating diabetes |
Aug, 2026
(3 years from now) | |
| US8329648 | ASTRAZENECA AB | Methods for treating diabetes and reducing body weight |
Aug, 2026
(3 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US7851502 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Aug, 2028
(5 years from now) | |
| US8721615 | ASTRAZENECA AB | Ampoule comprising an ampoule holder |
Jan, 2030
(7 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(7 years from now) | |
| US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(17 years from now) | |
Drugs and Companies using DAPAGLIFLOZIN ingredient
Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; treatment of type 2 diabetes mellitus in combination with exenatide; reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4; Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone; Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
5. Drug name - KOMBIGLYZE XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN1698601A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2010
(12 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1213028C | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1427826A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101479287B | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445A | ASTRAZENECA AB | Sglt2 Inhibitor Crystal Structure And Its Preparation Method |
Jun, 2027
(4 years from now) | |
| CN101479287A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773B | ASTRAZENECA AB | Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid |
Jun, 2027
(4 years from now) | |
| CN103145773A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445B | ASTRAZENECA AB | Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof |
Jun, 2027
(4 years from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200201154P3 | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN206543B | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1559710A3 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2995615B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP1559710B1 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825A2 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP2995615A1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825A3 | ASTRAZENECA AB | N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825B1 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP1559710A2 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP1261586B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP1261586A2 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP2069374B1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374A1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807A1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP3045466A1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374B2 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3045466B1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807B1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
| US9339472 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 1GM;EQ 2.5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 1GM;EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 500MG;EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Prescription |
6. Drug name - ONGLYZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN1698601A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2010
(12 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1213028C | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1427826A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101479287B | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445A | ASTRAZENECA AB | Sglt2 Inhibitor Crystal Structure And Its Preparation Method |
Jun, 2027
(4 years from now) | |
| CN101479287A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773B | ASTRAZENECA AB | Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid |
Jun, 2027
(4 years from now) | |
| CN103145773A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445B | ASTRAZENECA AB | Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof |
Jun, 2027
(4 years from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200201154P3 | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN206543B | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1559710A3 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2995615B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP1559710B1 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825A2 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP2995615A1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825A3 | ASTRAZENECA AB | N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825B1 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP1559710A2 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP1261586B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP1261586A2 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP2069374B1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374A1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807A1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP3045466A1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374B2 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3045466B1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807B1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7951400 | ASTRAZENECA AB | Coated tablet formulation and method |
Nov, 2028
(6 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| EQ 2.5MG BASE | TABLET;ORAL | Prescription |
| EQ 5MG BASE | TABLET;ORAL | Prescription |
7. Drug name - QTERN
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months from now) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(3 years from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(7 years from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN1698601A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2010
(12 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1213028C | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1427826A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101479287B | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445A | ASTRAZENECA AB | Sglt2 Inhibitor Crystal Structure And Its Preparation Method |
Jun, 2027
(4 years from now) | |
| CN101479287A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773B | ASTRAZENECA AB | Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid |
Jun, 2027
(4 years from now) | |
| CN103145773A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445B | ASTRAZENECA AB | Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof |
Jun, 2027
(4 years from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200201154P3 | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN206543B | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1559710A3 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2995615B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP1559710B1 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825A2 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP2995615A1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825A3 | ASTRAZENECA AB | N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825B1 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP1559710A2 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP1261586B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP1261586A2 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP2069374B1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374A1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807A1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP3045466A1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374B2 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3045466B1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807B1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| US8361972 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US8221786 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient
Treatment: Treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; Treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG;EQ 5MG BASE | TABLET;ORAL | Prescription |
| 10MG;EQ 5MG BASE | TABLET;ORAL | Prescription |
8. Drug name - QTERNMET XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| USRE44186 | ASTRAZENECA AB | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
Jul, 2023
(9 months from now) | |
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(3 years from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(7 years from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN1698601A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2010
(12 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1213028C | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1427826A | ASTRAZENECA AB | Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof |
Mar, 2021
(1 year, 6 months ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101479287B | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445A | ASTRAZENECA AB | Sglt2 Inhibitor Crystal Structure And Its Preparation Method |
Jun, 2027
(4 years from now) | |
| CN101479287A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773B | ASTRAZENECA AB | Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid |
Jun, 2027
(4 years from now) | |
| CN103145773A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445B | ASTRAZENECA AB | Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof |
Jun, 2027
(4 years from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200201154P3 | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN206543B | ASTRAZENECA AB | A Cyclopropyl-Fused Pyrrolidine-Based Compound |
Mar, 2021
(1 year, 6 months ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1559710A3 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2995615B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP1559710B1 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825A2 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP2995615A1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825A3 | ASTRAZENECA AB | N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP2272825B1 | ASTRAZENECA AB | Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation |
Mar, 2021
(1 year, 7 months ago) | |
| EP1559710A2 | ASTRAZENECA AB | Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use |
Mar, 2021
(1 year, 7 months ago) | |
| EP1261586B1 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP1261586A2 | ASTRAZENECA AB | Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use |
Mar, 2026
(3 years from now) | |
| EP2069374B1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374A1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807A1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP3045466A1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374B2 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3045466B1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807B1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8628799 | ASTRAZENECA AB | Coated tablet formulation and method |
Jul, 2025
(2 years from now) | |
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| US8716251 | ASTRAZENECA AB | Pharmaceutical formulations containing an SGLT2 inhibitor |
Mar, 2028
(5 years from now) | |
| US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(8 years from now) | |
Treatment: Treatment of type 2 diabetes mellitus
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG;1GM;EQ 2.5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 5MG;1GM;EQ 2.5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 5MG;1GM;EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
| 10MG;1GM;EQ 5MG BASE | TABLET, EXTENDED RELEASE;ORAL | Discontinued |
9. Drug name - XIGDUO XR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6515117 | ASTRAZENECA AB | C-aryl glucoside SGLT2 inhibitors and method |
Oct, 2025
(3 years from now) | |
| US7919598 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Dec, 2029
(7 years from now) | |
| CN1896088A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Jul, 2009
(13 years ago) | |
| CN101092409A | ASTRAZENECA AB | C-Glucosinolates Sglt2 Inhibitor And Method |
May, 2011
(11 years ago) | |
| CN1284793C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1407990A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| CN1653075A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN100534997C | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN102627676A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitor And Method |
May, 2023
(7 months from now) | |
| CN101628905A | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN101628905B | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2023
(7 months from now) | |
| CN103319445B | ASTRAZENECA AB | Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof |
Jun, 2027
(4 years from now) | |
| CN101479287A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773B | ASTRAZENECA AB | Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid |
Jun, 2027
(4 years from now) | |
| CN101479287B | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103145773A | ASTRAZENECA AB | Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| CN103319445A | ASTRAZENECA AB | Sglt2 Inhibitor Crystal Structure And Its Preparation Method |
Jun, 2027
(4 years from now) | |
| IN200200433P3 | ASTRAZENECA AB | A C-Aryl Glucoside |
Oct, 2020
(2 years ago) | |
| IN200700019I3 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
Jan, 2027
(4 years from now) | |
| EP1224195A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP1224195B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors |
Oct, 2020
(2 years ago) | |
| EP3045466A1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374B1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP2069374A1 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3045466B1 | ASTRAZENECA AB | (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP3363807A1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP3363807B1 | ASTRAZENECA AB | Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate |
Jun, 2027
(4 years from now) | |
| EP2069374B2 | ASTRAZENECA AB | Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes |
Jun, 2027
(4 years from now) | |
| EP1506211A4 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211B1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| EP1506211A1 | ASTRAZENECA AB | C-Aryl Glucoside Sglt2 Inhibitors And Method |
May, 2028
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8501698 | ASTRAZENECA AB | Crystal structures of SGLT2 inhibitors and processes for preparing same |
Jun, 2027
(4 years from now) | |
| US8685934 | ASTRAZENECA AB | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof |
May, 2030
(7 years from now) | |
| US9616028 | ASTRAZENECA AB | Bilayer tablet formulations |
Nov, 2030
(8 years from now) | |
Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 5MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 5MG;500MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 10MG;1GM | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 10MG;500MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.